Cover Image
Market Research Report

Global Hodgkin's Lymphoma Drugs Market 2019-2023

Published by TechNavio (Infiniti Research Ltd.) Product code 801147
Published Content info 113 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Hodgkin's Lymphoma Drugs Market 2019-2023
Published: February 22, 2019 Content info: 113 Pages
Description

About this market

Hodgkin's lymphoma is one of the most curable forms of lymphoma, with a patient survival rate of more than five years. The high unmet need for novel and innovative alternative treatment approaches. In addition, the introduction of target molecular hallmarks of this disease, including the aberrant phenotype of cancer cells, deregulated cancer pathways, and immune escape mechanisms. With an increased understanding of the fundamental biology of Hodgkin's lymphoma, companies have been able to develop drugs that are effective in treating the disease. This is expected to drive the market growth during the forecast period. Technavio's analysts have predicted that the hodgkin's lymphoma drugs market will register a CAGR of close to 16% by 2023.

Market Overview

Development of novel pipeline drugs

The increase in the prevalence of Hodgkin's lymphoma has led to a high unmet need for a strong pipeline of disease-modifying drugs. R&D activities are resulting in the availability of new drugs for the treatment of Hodgkin's lymphoma.

Treatment of Hodgkin's lymphoma patients with conjoint conditions

The treatment of Hodgkin's lymphoma has generally been successful and well-tolerated by patients. However, there are challenges associated with the treatment of patients that have Hodgkin's lymphoma with conjoint conditions, such as cardiac diseases, HIV infection, and pregnancy. Hodgkin's lymphoma is more common in patients with HIV. The presence of HIV in patients with Hodgkin's lymphoma can have a negative impact on treatment tolerance and prognosis.

For the detailed list of factors that will drive and challenge the growth of the Hodgkin's lymphoma drugs market during the 2019-2023, view our report.

Competitive Landscape

The market appears to be moderately concentrated and with the presence of limited vendors. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.

Table of Contents
Product Code: IRTNTR30809

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1. Preface
  • 2.2. Preface
  • 2.3. Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: PIPELINE ANALYSIS

PART 05: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 06: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 07: MARKET SEGMENTATION BY TYPE

  • Market segmentation by type
  • Comparison by type
  • Targeted therapy - Market size and forecast 2018-2023
  • Chemotherapy - Market size and forecast 2018-2023
  • Market opportunity by type

PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 12: MARKET TRENDS

  • Market trends

PART 13: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 14: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Bristol-Myers Squibb Company
  • Merck & Co., Inc.
  • ONO PHARMACEUTICAL CO., LTD.
  • Pfizer Inc.
  • Seattle Genetics, Inc.

PART 15: APPENDIX

  • Research methodology
  • List of abbreviations

PART 16: EXPLORE TECHNAVIO

Back to Top